Capricor Therapeutics, Inc.

NASDAQ
CAPR
Stock
Yield per half year: -45.33%
Dividend yield: 0%
Sector: Healthcare

Share chart Capricor Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).

more details
It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2007-02-13
ISIN US14070B3096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 10.25
Change price per day: -0.6679% (10.48)
Change price per week: -6.38% (11.12)
Change price per month: -18.86% (12.83)
Change price per 3 month: -28.01% (14.46)
Change price per half year: -45.33% (19.04)
Change price per year: +70.66% (6.1)
Change price per 3 year: +207.99% (3.38)
Change price per 5 year: +43.19% (7.27)
Change price per 10 year: +79.48% (5.8)
Change price per year to date: -26.07% (14.08)
All parameters

Grade

Underestimation
Title Value Grade
P/S 21.82 1
P/BV 3.34 5
P/E 0 0
EV/EBITDA -11.57 0
Total: 3.63
Efficiency
Title Value Grade
ROA, % -35.31 0
ROE, % -48.16 0
Total: 0
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA -0.0353 10
Total: 10
Growth impulse
Title Value Grade
Yield Revenue, % 7084.02 10
Yield Ebitda, % 200.48 10
Yield EPS, % 32.73 5
Total: 9
More

Main owners

Institutions Volume Share, %
Vanguard Group Inc 1 165 404 3.7
Woodline Partners LP 909 542 2.89
Blackrock Inc. 359 673 1.14
Geode Capital Management, LLC 316 198 1
Susquehanna International Group, LLP 149 115 0.47
Renaissance Technologies, LLC 146 321 0.46
Northern Trust Corporation 127 229 0.4
Osaic Holdings Inc 116 550 0.37
State Street Corporation 85 224 0.27
Bank Of New York Mellon Corporation 84 759 0.27

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman of the Board 120k 1956 (69 years)
Dr. Linda Marbán Ph.D. Co-Founder, President, CEO & Director 280.62k 1963 (62 years)
Mr. Anthony J. Bergmann M.B.A. CFO & Corporate Treasurer 437k 1986 (39 years)
Ms. Karen G. Krasney Executive VP, General Counsel & Secretary 426.72k 1953 (72 years)
Dr. Kristi A. H. Elliott Ph.D. Chief Science Officer N/A
Catherine Lee Kelleher Consultant N/A

About company

Address: United States, San Diego. CA, 10865 Road to the Cure - Open in google maps, Open in yandex maps
Website: https://www.capricor.com